PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks

AIMS: Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for patients at high/very high cardiovascular risk who are inadequately treated with maximally tolerated lipid-lowering therapies (LLTs). OBJECTIVES: We assessed the effectiveness and safety of the PCSK9i alir...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Am J Cardiovasc Drugs
Autori principali: Hollstein, Tim, Kassner, Ursula, Grenkowitz, Thomas, Schumann, Friederike, Bobbert, Thomas, Steinhagen-Thiessen, Elisabeth
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer International Publishing 2020
Soggetti:
Original Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7838077/
https://ncbi.nlm.nih.gov/pubmed/32514867
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40256-020-00411-3
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi